ＡＯＶＡINSTITUTEFORHUMANDATASCIENCEGlobal Trends inR&D2025Progress in RecapturingMomentumin Biopharma InnovationMARCH2025
IntroductionThelife sciencesinnovation ecosvstem has continued to evolve and expand asindustry adapts to a complex and dynamic range of geopolitical, technologicaand social uncertainties, and investment continues to flow into th e sector.Innovative science has also grown in paralle, as evidenced by anincreasingproportion of noveltherapeutic modalities in clinical trials and bv innovativeproducts receiving requlatory approval and reachina patients - with multioleimportant cell and gene therapy drugs having achieved recent successalongside new options for historically challenging indications. Despite theseadvances, improving the efficiency of R& D remains an important objective forbiopharmaceutical companies and significant opportunities exist to reducemedicine development times and increase probabilities of success,This reportsesthe trends in R&Dfundina.clinicabasedonproprietaryIQMIAdatabases and/or third-partytrial activity, and new druq approvals and launches. Itinformation. No proprietary sponsor trialinformationispresented.development,using arefreshedClinicalProgramThecontributions to thisreport fromTaskinAhmed,Productivity Index, while also providing insights onLucy Haggerty, SrinidhiBC, TanyaBhardwal,contributing factors and enablers. Operationallyaddressable cycle timecomponents areinvestigatedChrisBamford,RachaelFones, Julla Kern, Bhagyashreebyexaminingclinicaltrialtimelinesinthe broaderNawar, Urvashi Porwal,Jamile Pritchett, and dozens ofcontextof atypicalmedicinedevelopmentprogram,demonstrating critical within- and between-trialcomponentsthatcanbetargetedtoaccelerateFindOutMoredevelooment.The continuedsignificance ofemergingblopharmacompanies and ofgeographicalshifts inIfyouwishtoreceivefuturereportsfromtheIQVIclinical trialactivity are revisited throuahoutInstitute for Human Data Sclenceorjoinourmaiing list,visitiqviainstituteorg,The research included in this reportwas undertakerindependentlybytheIQVIAInstituteforHumanMURRAYAITKENData Sclence as apublic service, without industryorExecutiveDirectorgovernmentfunding.The analyticsinthis reportareIQVIAInstituteforHumanDataScenceREFERENCINGTHISREPORTPleaseuse thisformatwhenreferencingcontentfromthisreportSoure:10VAInstituteforHumanDataScience,GlobalTrendsinR&LD2025;Progessinrecapturingmomentuminbipharmoinnovation,Morch,202.Aoilahe from wwigphbinstiteorgC20251QVA and its affiliates. Allreproduction rights, quotations, broadcasting,publicationsreserved.No part of this publicationmaybereproduced orexpress written consentofIQVIA and the IQVIAInstitute.GlobalTrends in R&D 2025;Progress in Recapturing Momentumin Biopharma lnovation
Table of ContentsOverviewR&DfundingClinicaltrialactivityNew drug approvals and launchessClinicaldevelopmentproductivityProductivityenablersNotesonsourcesMethodologiesReferencesAbouttheauthorsAbouttheInstitute
OverviewR&DFUNDINGTotalR&Dexpenditureoflagephamaceutcalcompanies continued to increase in 2024, both inBlopharma fundinglevels in the p...
